



(12) Translation of  
European patent specification

(11) NO/EP 3114118 B1

NORWAY

(19) NO  
(51) Int Cl.  
*C07D 403/12 (2006.01)*  
*C07D 211/58 (2006.01)*  
*C07D 211/60 (2006.01)*  
*C07D 211/94 (2006.01)*  
*C07D 211/96 (2006.01)*  
*C07D 213/00 (2006.01)*  
*C07D 239/26 (2006.01)*  
*C07D 241/12 (2006.01)*  
*C07D 401/06 (2006.01)*  
*C07D 401/12 (2006.01)*  
*C07D 401/14 (2006.01)*  
*C07D 405/12 (2006.01)*  
*C07D 405/14 (2006.01)*  
*C07D 409/12 (2006.01)*  
*C07D 409/14 (2006.01)*  
*C07D 413/12 (2006.01)*  
*C07D 417/12 (2006.01)*  
*C07D 417/14 (2006.01)*  
*C07D 471/04 (2006.01)*

**Norwegian Industrial Property Office**

---

(45) Translation Published 2020.10.26  
(80) Date of The European Patent Office Publication of the Granted Patent 2020.07.22  
(86) European Application Nr. 15711614.6  
(86) European Filing Date 2015.03.06  
(87) The European Application's Publication Date 2017.01.11  
(30) Priority 2014.03.07, US, 201461949664 P  
(84) Designated Contracting States: AL ; AT ; BE ; BG ; CH ; CY ; CZ ; DE ; DK ; EE ; ES ; FI ; FR ; GB ; GR ; HR ; HU ; IE ; IS ; IT ; LI ; LT ; LU ; LV ; MC ; MK ; MT ; NL ; NO ; PL ; PT ; RO ; RS ; SE ; SI ; SK ; SM ; TR  
Designated Extension States: BA ; ME  
Designated Validation States: MA  
(73) Proprietor Helsinn Healthcare SA, Via Pian Scairolo 9, 6912 Lugano-Pazzallo, Sveits  
(72) Inventor GIULIANO, Claudio, Via Prudenziiana 28/A, 22100 Como, Italia  
GARCIA RUBIO, Silvina, 7 Bellflower Ct., Princeton, NJ 08540, USA  
DAINA, Antoine, Quartier SorgeBatiment Genopode, 1015 Lausanne, Sveits  
GUAINAZZI, Angelo, 170 Wood Avenue South5th Floor, Iselin, NJ 08830, USA  
PIETRA, Claudio, Via Scalabrini No. 56, 22100 Como, Italia

(74) Agent or Attorney PROTECTOR IP AS, Pilestredet 33, 0166 OSLO, Norge

---

(54) Title **P-SUBSTITUTED ASYMMETRIC UREAS AND MEDICAL USES THEREOF**

(56) References

Cited:


US-A1- 2008 227 780  
WO-A2-2009/039461  
US-B1- 6 399 619  
WO-A1-2006/014136  
WO-A1-2012/113103  
WO-A2-2004/064738  
WO-A1-2011/060397

LI B ET AL: "Studies on the structure-activity relationship of 1,3,3,4-tetra-substituted pyrrolidine embodied CCR5 receptor antagonists. Part 2: Discovery of highly potent anti-HIV agents", BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, PERGAMON, AMSTERDAM, NL, vol. 20, no. 17, 19 May 2010 (2010-05-19), pages 5334-5336, XP027207986, ISSN: 0960-894X [retrieved on 2010-05-19]

BERLIN M ET AL: "Reduction of hERG inhibitory activity in the 4-piperidinyl urea series of H3 antagonists", BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, PERGAMON, AMSTERDAM, NL, vol. 20, no. 7, 28 January 2010 (2010-01-28), pages 2359-2364, XP026971078, ISSN: 0960-894X [retrieved on 2010-01-28]

Enclosed is a translation of the patent claims in Norwegian. Please note that as per the Norwegian Patents Acts, section 66i the patent will receive protection in Norway only as far as there is agreement between the translation and the language of the application/patent granted at the EPO. In matters concerning the validity of the patent, language of the application/patent granted at the EPO will be used as the basis for the decision. The patent documents published by the EPO are available through Espacenet (<http://worldwide.espacenet.com>) or via the search engine on our website here: <https://search.patentstyret.no/>

1. En forbindelse med formal I:



eller et farmasøytisk akseptabelt salt derav, hvor:

en prikket linje indikerer en valgfri binding;

X er CH;

Z er NR<sup>9</sup>;

R<sup>1</sup> er H, C<sub>1-6</sub> alkyl, benzyl, OH, eller C<sub>1-6</sub> alkoksy, hvor nevnte C<sub>1-6</sub> alkyl, benzyl, eller C<sub>1-6</sub> alkoksy ikke er substituert eller substituert med 1-3 substituenter valgt fra halo, OH, C<sub>1-6</sub> alkyl, C<sub>1-6</sub> alkoxsy, C<sub>1-6</sub> hydroksyalkyl, CO(C<sub>1-6</sub> alkyl), CHO, CO<sub>2</sub>H, CO<sub>2</sub>(C<sub>1-6</sub> alkyl), og C<sub>1-6</sub> haloalkyl;

R<sup>2</sup> er H;

R<sup>3</sup> og R<sup>4</sup> er hver, uavhengig, H, CN, halo, CHO, CO<sub>2</sub>H, C<sub>1-6</sub> alkyl, C<sub>1-6</sub> hydroksyalkyl, C<sub>1-6</sub> alkylsykloalkyl, C<sub>1-6</sub> haloalkyl, C<sub>1-6</sub> alkoxsy, CO(C<sub>1-6</sub> alkyl), CO<sub>2</sub>(C<sub>1-6</sub> alkyl), eller CONR<sup>12</sup>R<sup>13</sup>;

eller R<sup>3</sup> og R<sup>4</sup> tatt sammen med C atomet til hvilket de er festet danner en 3-6-leddet ring;

R<sup>5</sup> er pyridyl, pyridazinyl, pyrazinyl, pyrimidinyl eller C<sub>2-6</sub> alkynyl, som hver ikke er substituert eller substituert med 1-3 substituenter valgt fra halo, CN, OH, NO<sub>2</sub>, Si(CH<sub>3</sub>)<sub>4</sub>, CHO, og CO<sub>2</sub>H, eller CO(C<sub>1-6</sub> alkyl), CO<sub>2</sub>(C<sub>1-6</sub> alkyl), NR<sup>14</sup>R<sup>15</sup>, NHCONR<sup>14</sup>R<sup>15</sup>, CONR<sup>14</sup>R<sup>15</sup>, CH=NOH, C<sub>1-6</sub> alkyl, C<sub>1-6</sub> alkoxsy, C<sub>1-6</sub> haloalkyl, C<sub>1-6</sub> hydroksyalkyl, C<sub>2-6</sub> alkenyl, C<sub>2-6</sub> alkynyl, aryl, sykloalkyl, heteroaryl, og heterosykloalkyl;

R<sup>6</sup> er H;

R<sup>7</sup> er halo;

R<sup>8</sup> er methyl;

R<sup>9</sup> er H, C<sub>1-6</sub> alkyl, CO(C<sub>1-6</sub> alkyl), CHO, CO<sub>2</sub>H, eller CO<sub>2</sub>(C<sub>1-6</sub> alkyl);

R<sup>12</sup> og R<sup>13</sup> er hver, uavhengig, H eller C<sub>1-6</sub> alkyl;

R<sup>14</sup> og R<sup>15</sup> er hver, uavhengig H, C<sub>1-6</sub> alkyl, CO(C<sub>1-6</sub> alkyl), CO(heteroaryl), heteroaryl, eller sykloalkyl;

r er 2;


s er 0-4; og

n er 0-3.


2. Forbindelsen i henhold til krav 1, hvor Z er N(C<sub>1-6</sub> alkyl).
3. Forbindelsen i henhold til krav 1, hvor Z er NCH<sub>3</sub>.
4. Forbindelse i henhold til krav 1, hvor R<sup>1</sup> er H<sub>3</sub>, metoksy, etoksy eller propoksy; eller R<sup>1</sup> er benzyl eventuelt substituert med CO<sub>2</sub>(C<sub>1-6</sub> alkyl) eller C<sub>1-6</sub> hydroksyalkyl.
5. Forbindelsen i henhold til krav 1, hvor R<sup>3</sup> og R<sup>4</sup> er hver, uavhengig valgt fra C<sub>1-6</sub> alkyl, CN, C<sub>1-6</sub>alkylsykloalkyl, CO<sub>1-6</sub>hydroksyalkyl, CO<sub>2</sub>(C<sub>1-6</sub>alkyl), C<sub>1-6</sub>haloalkyl og CONH<sub>2</sub>.
6. Forbindelsen i henhold til krav 5, hvor nevnte C<sub>1-6</sub> alkyl er methyl eller etyl.
7. Forbindelsen i henhold til krav 5, hvor nevnte C<sub>1-6</sub> alkylsykloalkyl er C<sub>1</sub> alkylsyklopropyl.
8. Forbindelsen i henhold til krav 5, hvor nevnte C<sub>1-6</sub> hydroksyalkyl er C<sub>1</sub> hydroksyalkyl eventuelt substituert med en substituert eller usubstituert benzyl gruppe.
9. Forbindelsen i henhold til krav 5, hvor nevnte CO<sub>2</sub>(C<sub>1-6</sub> alkyl) er CO<sub>2</sub>CH<sub>3</sub>.
10. Forbindelsen i henhold til krav 5, hvor nevnte C<sub>1-6</sub> haloalkyl er CF<sub>3</sub>.
11. Forbindelsen i henhold til krav 1, hvor R<sup>3</sup> og R<sup>4</sup> tatt sammen med C-atomet til hvilke de er festet for å danne en syklopropyl ring eller en tetrahydropyranyl ring.

12. Forbindelsen i henhold til krav 1 hvor R<sup>7</sup> er Cl eller F.

13. En forbindelse i henhold til krav 1, med Formel II eller III:










eller et farmasøytisk akseptabelt salt derav,



eller et farmasøytisk akeptabelt salt derav,

14. Forbindelsen i henhold til krav 1, valgt fra gruppen bestående av:

Forbindelse nr.	Kjemisk struktur	Kjemisk navn
5 H0496		3-(1-(2,3-diklor-4-(pyridin-3-yl)fenyl) ethyl)-1-methyl-1-(1-metylpiriperidin-4-yl) urea
10 H0539		metyl 4-((3-(1-(2,3-diklor-4-(pyridin-3-yl)fenyl)ethyl)-1-(1-metylpiriperidin-4-yl)ureido)metyl)benzoat
15 H0546		3-(1-(2,3-diklor-4-(pyridin-3-yl)fenyl) ethyl)-1-(4-(hydroksymetyl)benzyl)-1-(1-metylpiriperidin-4-yl)urea
20 H0527		3-(1-(2,3-diklor-4-(pyridin-3-yl)fenyl) ethyl)-1-(1,3-dimetylpiriperidin-4-yl)-1-metylurea
25 H0497		3-(1-(2,3-diklor-4-(pyridin-4-yl)fenyl) ethyl)-1-methyl-1-(1-metylpiriperidin-4-yl) urea
30 H0650		3-(1-(2,3-diklor-4-(pyridin-2-yl)fenyl) ethyl)-1-methyl-1-(1-metylpiriperidin-4-yl) urea
35 H0849		3-(1-(2,3-diklor-4-(5-cyclopropylpyridin-2-yl)fenyl)ethyl)-1-methyl-1-(1-metylpiriperidin-4-yl)urea
40 H0511		3-(1-(2,3-diklor-4-(6-metoksypyridin-3-yl)fenyl)ethyl)-1-methyl-1-(1-metylpiriperidin-4-yl)urea

Forbindelse nr.	Kjemisk struktur	Kjemisk navn
10 H0820		3-(1-(2,3-diklor-4-(6-syklopropylpyridin-3-yl)fenyl)ethyl)-1-metyl-1-(1-metylpiriperidin-4-yl)urea
15 H0613		3-(1-(2,3-diklor-4-(5-cyanopyridin-3-yl)fenyl)ethyl)-1-metyl-1-(1-metylpiriperidin-4-yl)urea
20 H0614		3-(1-(2,3-diklor-4-(5-fluoropyridin-3-yl)fenyl)ethyl)-1-metyl-1-(1-metylpiriperidin-4-yl)urea
25 H0635		metyl 5-(2,3-diklor-4-(1-(3-metyl-3-(1-metylpiriperidin-4-yl)ureido)ethyl)fenyl)nikotinat
30 H0636		3-(1-(2,3-diklor-4-(5-(hydroksymetyl)pyridin-3-yl)fenyl)ethyl)-1-metyl-1-(1-metylpiriperidin-4-yl)urea
35 H0637		3-(1-(2,3-diklor-4-(5-(difluormetyl)pyridin-3-yl)fenyl)ethyl)-1-metyl-1-(1-metylpiriperidin-4-yl)urea
40 H0638		3-(1-(2,3-diklor-4-(5-(fluormetyl)pyridin-3-yl)fenyl)ethyl)-1-metyl-1-(1-metylpiriperidin-4-yl)urea

5








Forbindelse nr.	Kjemisk struktur	Kjemisk navn
10 H0639		3-(1-(2,3-diklor-4-(5-metylpyridin-3-yl)fenyl)ethyl)-1-metyl-1-(1-metylpiridin-4-yl)urea
15 H0642		3-(1-(2,3-diklor-4-(5-formylpyridin-3-yl)fenyl)ethyl)-1-metyl-1-(1-metylpiridin-4-yl)urea
20 H0704		3-(1-(4-(5-aminopyridin-3-yl)-2,3-diklorfenyl)ethyl)-1-metyl-1-(1-metylpiridin-4-yl)urea
25 H0707		3-(1-(4-(5-(1H-pyrazol-4-yl)pyridin-3-yl)-2,3-diklorfenyl)ethyl)-1-metyl-1-(1-metylpiridin-4-yl)urea
30 H0711		3-(1-(4-(5-(1H-imidazol-4-yl)pyridin-3-yl)-2,3-diklorfenyl)ethyl)-1-metyl-1-(1-metylpiridin-4-yl)urea
35 H0716		3-(1-(2,3-diklor-4-(5-(thiazol-5-yl)pyridin-3-yl)fenyl)ethyl)-1-metyl-1-(1-metylpiridin-4-yl)urea
40 H0717		3-(1-(2,3-diklor-4-(5-(thiophen-2-yl)pyridin-3-yl)fenyl)ethyl)-1-metyl-1-(1-metylpiridin-4-yl)urea








Forbindelse nr.	Kjemisk struktur	Kjemisk navn
10 H0718		3-(1-(2,3-diklor-4-(5-syklopentylypyridin-3-yl)fenyl)etyl)-1-metyl-1-(1-metylpiridin-4-yl)urea
15 H0719		3-(1-(2,3-diklor-4-(5-(pyrrolidin-1-yl)pyridin-3-yl)fenyl)etyl)-1-metyl-1-(1-metylpiridin-4-yl)urea
20 H0715		3-(1-(2,3-diklor-4-(5-etylpyridin-3-yl)fenyl)etyl)-1-metyl-1-(1-metylpiridin-4-yl)urea
25 H0706		3-(1-(2,3-diklor-4-(5-vinylpyridin-3-yl)fenyl)etyl)-1-metyl-1-(1-metylpiridin-4-yl)urea
30 H0710		3-(1-(2,3-diklor-4-(5-ethynylpyridin-3-yl)fenyl)etyl)-1-metyl-1-(1-metylpiridin-4-yl)urea
35 H0666		3-(cyano(2,3-diklor-4-(5-cyanopyridin-3-yl)fenyl)metyl)-1-metyl-1-(1-metylpiridin-4-yl)urea
40 H0739		3-((4-(5-(1H-pyrrol-2-yl)pyridin-3-yl)-2,3-diklorfenyl)(cyano)metyl)-1-metyl-1-(1-metylpiridin-4-yl)urea








Forbindelse nr.	Kjemisk struktur	Kjemisk navn
10 H0667		3-(1-(2,3-diklor-4-(5-cyanopyridin-3-yl)fenyl)ethyl)-1-hydroksy-1-(1-metylpiriperidin-4-yl)urea
15 H0646		(E)-3-(1-(2,3-diklor-4-(5((hydroksyimino)metyl)pyridin-3-yl)fenyl)ethyl)-1-metyl-1-(1-metylpiriperidin-4-yl)urea
20 H0516		3-(1-(2,3-diklor-4-(pyrimidin-5-yl)fenyl)ethyl)-1-metyl-1-(1-metylpiriperidin-4-yl)urea
25 H0649		3-(1-(2,3-diklor-4-(2-metoksypyrimidin-5-yl)fenyl)ethyl)-1-metyl-1-(1-metylpiriperidin-4-yl)urea
30 H0797		3-(1-(2,3-diklor-4-(2-hydroksypyrimidin-5-yl)fenyl)ethyl)-1-metyl-1-(1-metylpiriperidin-4-yl)urea
35 H0798		3-(1-(4-(2-aminopyrimidin-5-yl)-2,3-diklorfenyl)ethyl)-1-metyl-1-(1-metylpiriperidin-4-yl)urea
40 H0800		3-(1-(2,3-diklor-4-(2-fluoropyrimidin-5-yl)fenyl)ethyl)-1-metyl-1-(1-metylpiriperidin-4-yl)urea








Forbindelse nr.	Kjemisk struktur	Kjemisk navn
10 H0801		3-(1-(2,3-diklor-4-(2-klorpyrimidin-5-yl)fenyl)ethyl)-1-metyl-1-(1-metylpiriperidin-4-yl)urea
15 H0802		3-(1-(2,3-diklor-4-(2-cyanopyrimidin-5-yl)fenyl)ethyl)-1-metyl-1-(1-metylpiriperidin-4-yl)urea
20 H0803		3-(1-(4-(2-(1H-imidazol-1-yl)pyrimidin-5-yl)-2,3-diklorfenyl)ethyl)-1-metyl-1-(1-metylpiriperidin-4-yl)urea
25 H0804		3-(1-(2,3-diklor-4-(2-(dimethylamino)pyrimidin-5-yl)fenyl)ethyl)-1-metyl-1-(1-metylpiriperidin-4-yl)urea
30 H0805		3-(1-(2,3-diklor-4-(2-(syklopropylamino)pyrimidin-5-yl)fenyl)ethyl)-1-metyl-1-(1-metylpiriperidin-4-yl)urea
35 H0806		3-(1-(2,3-diklor-4-(2-(methylamino)pyrimidin-5-yl)fenyl)ethyl)-1-metyl-1-(1-metylpiriperidin-4-yl)urea

Forbindelse nr.	Kjemisk struktur	Kjemisk navn
10 H0854		3-(1-(2,3-diklor-4-(2-syklopropylpyrimidin-5-yl)fenyl)ethyl)-1-metyl-1-(1-metylpiriperidin-4-yl)urea
15 H0813		3-(1-(2,3-diklor-4-(2-(pyrrolidin-1-yl)pyrimidin-5-yl)fenyl)ethyl)-1-metyl-1-(1-metylpiriperidin-4-yl)urea
20 H0703		3-(1-cyano-1-(2,3-diklor-4-(pyrimidin-5-yl)fenyl)ethyl)-1-metyl-1-(1-metylpiriperidin-4-yl)urea
25 H0709		3-(cyano(2,3-diklor-4-(pyrimidin-5-yl)fenyl)methyl)-1-metoksy-1-(1-metylpiriperidin-4-yl)urea
30 H0663		3-(1-(2,3-diklor-4-(2,4-dimetoksypyrimidin-5-yl)fenyl)ethyl)-1-metyl-1-(1-metylpiriperidin-4-yl)urea
35 H0624		3-(1-(2,3-diklor-4-(pyrimidin-5-yl)fenyl)ethyl)-1-hydroksy-1-(1-metylpiriperidin-4-yl)urea
40 H0662		metyl 2-(2,3-diklor-4-(pyrimidin-5-yl)fenyl)-2-(3-metyl-3-(1-metylpiriperidin-4-yl)ureido)acetat

Forbindelse nr.	Kjemisk struktur	Kjemisk navn
5 10 15 20 25 30 35 40 45 50 55	H0670  H0673  H0631  H0686  H0619  H0768  H0808 	3-(1-(2,3-diklor-4-(pyrimidin-5-yl)fenyl)-2-hydroksyethyl)-1-metyl-1-(1-methylpiperidin-4-yl)urea 3-(1-(2,3-diklor-4-(pyrimidin-5-yl)fenyl)syklopropyl)-1-metyl-1-(1-methylpiperidin-4-yl)urea 3-(cyano(2,3-diklor-4-(pyrimidin-5-yl)fenyl)metyl)-1-metyl-1-(1-methylpiperidin-4-yl)urea 3-(1-(2,3-diklor-4-(pyrimidin-5-yl)fenyl)-2,2,2-trifluoretyl)-1-metyl-1-(1-methylpiperidin-4-yl)urea 3-(1-(2,3-diklor-4-(pyrimidin-2-yl)fenyl) ethyl)-1-metyl-1-(1-methylpiperidin-4-yl) urea 3-(1-(2,3-diklor-4-(pyrimidin-4-yl)fenyl) ethyl)-1-metyl-1-(1-methylpiperidin-4-yl) urea 3-(1-(2,3-diklor-4-(6-metylpyrimidin-4-yl)fenyl)ethyl)-1-metyl-1-(1-methylpiperidin-4-yl)urea

Forbindelse nr.	Kjemisk struktur	Kjemisk navn
10 H0700		3-(1-(2,3-diklor-4-(pyrazin-2-yl)fenyl) ethyl)-1-metyl-1-(1-metylpiriperidin-4-yl) urea
15 H0816		(S)-3-(1-(2,3-diklor-4-(pyrazin-2-yl)fenyl) ethyl)-1-metyl-1-(1-metylpiriperidin-4-yl) urea
20 H0817		(R)-3-(1-(2,3-diklor-4-(pyrazin-2-yl)fenyl) ethyl)-1-metyl-1-(1-metylpiriperidin-4-yl) urea
25 H0743		3-(1-(2,3-diklor-4-(pyrazin-2-yl)fenyl) ethyl)-1-metoksy-1-(1-metylpiriperidin-4-yl) urea
30 H0750		3-(1-(2,3-diklor-4-(pyrazin-2-yl)fenyl) ethyl)-1-etoksy-1-(1-metylpiriperidin-4-yl) urea
35 H0756		3-(1-(2,3-diklor-4-(pyrazin-2-yl)fenyl) ethyl)-1-hydroksy-1-(1-metylpiriperidin-4-yl) urea
40 H0824		3-(1-(2,3-diklor-4-(pyrazin-2-yl)fenyl) ethyl)-1-metyl-1-((R)-1,3,3-trimetylpiriperidin-4-yl)urea

Forbindelse nr.	Kjemisk struktur	Kjemisk navn
10 H0890		3-((S)-1-(2,3-diklor-4-(pyrazin-2-yl)fenyl)ethyl)-1-metyl-1-((R)-1,3,3-trimetylpiperidin-4-yl)urea
15 H0858		3-(1-(2,3-diklor-4-(pyrazin-2-yl)fenyl)propyl)-1-metyl-1-((R)-1,3,3-trimetylpiperidin-4-yl)urea
20 H0865		3-(1-(2,3-diklor-4-(pyrazin-2-yl)fenyl)-2,2,2-trifluoretyl)-1-metyl-1-((R)-1,3,3-trimetylpiperidin-4-yl)urea
25 H0825		1-benzyl-3-(1-(2,3-diklor-4-(pyrazin-2-yl)fenyl)ethyl)-1-(1-metylpirperidin-4-yl)urea
30 H0826		3-(1-(2,3-diklor-4-(pyrazin-2-yl)fenyl)ethyl)-1-ethyl-1-(1-metylpirperidin-4-yl)urea
35 H0889		(S)-3-(1-(2,3-diklor-4-(pyrazin-2-yl)fenyl)ethyl)-1-ethyl-1-(1-metylpirperidin-4-yl)urea
40 H0896		3-(1-(2,3-diklor-4-(pyrazin-2-yl)fenyl)propyl)-1-ethyl-1-(1-metylpirperidin-4-yl)urea








Forbindelse nr.	Kjemisk struktur	Kjemisk navn
10 H0827		3-(1-(2,3-diklor-4-(pyrazin-2-yl)fenyl) ethyl)-1-(1-metylpiriperidin-4-yl)-1-propylurea
15 H0829		3-(1-(2,3-diklor-4-(pyrazin-2-yl)fenyl) propyl)-1-metyl-1-(1-methylpiperidin-4-yl) urea
20 H0859		(R)-3-(1-(2,3-diklor-4-(pyrazin-2-yl)fenyl) propyl)-1-metyl-1-(1-methylpiperidin-4-yl) urea (single enantiomer)
25 H0860		(S)-3-(1-(2,3-diklor-4-(pyrazin-2-yl)fenyl) propyl)-1-metyl-1-(1-methylpiperidin-4-yl) urea (single enantiomer)
30 H0922		metyl 2-(2,3-diklor-4-(pyrazin-2-yl) fenyl)-2-(3-metyl-3-(1-methylpiriperidin-4-yl)ureido)acetate
35 H0924		3-(1-(2,3-diklor-4-(pyrazin-2-yl)fenyl)-2-hydroksyethyl)-1-metyl-1-(1-methylpiperidin-4-yl)urea
40 H0830		3-(1-(2,3-diklor-4-(pyrazin-2-yl)fenyl)-2,2,2-trifluoretyl)-1-metyl-1-(1-methylpiperidin-4-yl)urea








Forbindelse nr.	Kjemisk struktur	Kjemisk navn
10 H0899		(S)-3-(1-(2,3-diklor-4-(pyrazin-2-yl)fenyl)-2,2,2-trifluoretyl)-1-metyl-1-(1-metylpiriperidin-4-yl)urea
15 H0900		(R)-3-(1-(2,3-diklor-4-(pyrazin-2-yl)fenyl)-2,2,2-trifluoretyl)-1-metyl-1-(1-metylpiriperidin-4-yl)urea
20 H0909		3-(1-(2,3-diklor-4-(pyrazin-2-yl)fenyl)-2,2,2-trifluoretyl)-1-etyl-1-(1-metylpiriperidin-4-yl)urea
25 H0856		3-(1-(3-klor-2-fluor-4-(pyrazin-2-yl)fenyl)ethyl)-1-metyl-1-(1-metylpiriperidin-4-yl)urea
30 H0815		3-(1-(2,3-diklor-4-(6-metylpyrazin-2-yl)fenyl)ethyl)-1-metyl-1-(1-metylpiriperidin-4-yl)urea
35 H0831		3-(1-(2,3-diklor-4-(3-metylpyrazin-2-yl)fenyl)ethyl)-1-metyl-1-(1-metylpiriperidin-4-yl)urea
40 H0843		3-(1-(2,3-diklor-4-(3-metylpyrazin-2-yl)fenyl)ethyl)-1-metyl-1-((R)-1,3,3-trimetylpiriperidin-4-yl)urea

Forbindelse nr.	Kjemisk struktur	Kjemisk navn
10 H0738		3-(1-(2,3-diklor-4-(6-metoksyprazin-2-yl)fenyl)ethyl)-1-metyl-1-(1-metylpiridin-4-yl)urea
15 H0780		3-(1-(4-(6-aminoprazin-2-yl)-2,3-diklorfenyl)ethyl)-1-metyl-1-(1-metylpiridin-4-yl)urea
20 H0786		3-(1-(2,3-diklor-4-(6-(klormetyl)prazin-2-yl)fenyl)ethyl)-1-metyl-1-(1-metylpiridin-4-yl)urea
25 H0791		3-(1-(2,3-diklor-4-(6-klorprazin-2-yl)fenyl)ethyl)-1-metyl-1-(1-metylpiridin-4-yl)urea
30 H0795		3-(1-(2,3-diklor-4-(6-fluoroprazin-2-yl)fenyl)ethyl)-1-metyl-1-(1-metylpiridin-4-yl)urea
35 H0847		(S)-3-(1-(2,3-diklor-4-(6-fluoroprazin-2-yl)fenyl)ethyl)-1-metyl-1-(1-metylpiridin-4-yl)urea
40 H0848		(R)-3-(1-(2,3-diklor-4-(6-fluoroprazin-2-yl)fenyl)ethyl)-1-metyl-1-(1-metylpiridin-4-yl)urea







Forbindelse nr.	Kjemisk struktur	Kjemisk navn
10 H0863		3-(1-(2,3-diklor-4-(6-fluorpyrazin-2-yl) fenyl)propyl)-1-metyl-1-(1-methylpiperidin-4-yl)urea
15 H0908		3-(1-(2,3-diklor-4-(6-fluorpyrazin-2-yl) fenyl)-2,2,2-trifluoretyl)-1-metyl-1-(1-methylpiperidin-4-yl)urea
20 H0840		3-(1-(2,3-diklor-4-(3-fluorpyrazin-2-yl) fenyl)ethyl)-1-metyl-1-(1-methylpiperidin-4-yl)urea
25 H0910		3-(1-(2,3-diklor-4-(6-(trifluormetyl) pyrazin-2-yl)fenyl)ethyl)-1-metyl-1-(1-methylpiperidin-4-yl)urea
30 H0788		3-(1-(2,3-diklor-4-(6-cyanopyrazin-2-yl) fenyl)ethyl)-1-metyl-1-(1-methylpiperidin-4-yl)urea
35 H0789		methyl6-(2,3-diklor-4-(1-(3-metyl-3-(1-methylpiperidin-4-yl)ureido)ethyl)fenyl) pyrazin-2-karboksylate
40 H0760		5-(2,3-diklor-4-(1-(3-metyl-3-(1-methylpiperidin-4-yl)ureido)ethyl)fenyl) pyrazin-2-carboxam ide







Forbindelse nr.	Kjemisk struktur	Kjemisk navn
10 H0769		metyl 5-(2,3-diklor-4-(1-(3-metyl-3-(1-metylpiridin-4-yl)ureido)ethyl)fenyl) pyrazin-2-karboksylat
20 H0771		5-(2,3-diklor-4-(1-(3-metyl-3-(1-metylpiridin-4-yl)ureido)ethyl)fenyl)-N,N-dimetylpyrazin-2-karboksamide
30 H0770		3-(1-(2,3-diklor-4-(5-hydroksymetyl)pyrazin-2-yl)fenyl)-1-methyl-1-(1-methylpiperidin-4-yl)urea
35 H0729		3-(1-(2,3-diklor-4-(pyridazin-3-yl)fenyl)ethyl)-1-methyl-1-(1-methylpiperidin-4-yl)urea
40 H0783		3-(1-(2,3-diklor-4-(pyridazin-4-yl)fenyl)ethyl)-1-methyl-1-(1-methylpiperidin-4-yl)urea
45 H0607		3-(1-(2,3-diklor-4-(5-metoksypridin-3-yl)fenyl)ethyl)-1-methyl-1-(1-methylpiperidin-4-yl)urea
55 H0695		3-(1-(4-(5-bromopyridin-3-yl)-2,3-diklorfenyl)ethyl)-1-methyl-1-(1-methylpiperidin-4-yl)urea


Forbindelse nr.	Kjemisk struktur	Kjemisk navn
5 10 15 20 25 30 35 40 45 50 55	 <p>Chemical structure of compound H0635: A piperidin-4-ylmethyl group attached to a ureido group (-CONHNHCO-), which is further attached to a 4-(3-methyl-1-(2,3-dichlorophenyl)propyl) group, which is attached to a 3-(2,3-dichlorophenyl)pyridine-5-carboxymethyl group.</p>	metyl 5-(2,3-diklor-4-(1-(3-metyl-3-(1-metylpiridin-4-yl)ureido)etyl)fenyl)nikotinat
	 <p>Chemical structure of compound H0690: Similar to H0635, but the carboxymethyl group is replaced by a methyl carbamate group (-CONHMe).</p>	3-(1-(4-(5-acetylpyridin-3-yl)-2,3-diklorfenyl)etyl)-1-metyl-1-(1-metylpiridin-4-yl)urea
	 <p>Chemical structure of compound H0735: Similar to H0635, but the pyridine ring at position 3 has a 2-pyrimidinyl group attached to its 5-position.</p>	3-(1-(2,3-diklor-4-(5-(pyrimidin-2-yl)pyridin-3-yl)fenyl)etyl)-1-metyl-1-(1-metylpiridin-4-yl)urea
	 <p>Chemical structure of compound H0746: Similar to H0635, but the pyridine ring at position 3 has a furan-3-yl group attached to its 5-position.</p>	3-(1-(2,3-diklor-4-(5-(furan-3-yl)pyridin-3-yl)fenyl)etyl)-1-metyl-1-(1-metylpiridin-4-yl)urea
	 <p>Chemical structure of compound H0747: Similar to H0635, but the pyridine ring at position 3 has a thien-3-yl group attached to its 5-position.</p>	3-(1-(2,3-diklor-4-(5-(thiofen-3-yl)pyridin-3-yl)fenyl)etyl)-1-metyl-1-(1-metylpiridin-4-yl)urea
	 <p>Chemical structure of compound H0765: Similar to H0635, but the pyridine ring at position 3 has a cyclopropyl group attached to its 5-position.</p>	3-(1-(2,3-diklor-4-(5-syklopropylpyridin-3-yl)fenyl)etyl)-1-metyl-1-(1-metylpiridin-4-yl)urea
	 <p>Chemical structure of compound H0766: Similar to H0635, but the pyridine ring at position 3 has a nitro group (-NO<sub>2</sub>) attached to its 5-position.</p>	3-(1-(2,3-diklor-4-(5-nitropyridin-3-yl)fenyl)etyl)-1-metyl-1-(1-metylpiridin-4-yl)urea

Forbindelse nr.	Kjemisk struktur	Kjemisk navn
5 10 15 20 25 30 35 40 45 50	H0608  H0616  H0618  H0602  H0603  H0832  H0852 	3-(1-(2,3-diklor-4-(6-isopropoksypyridin-3-yl)fenyl)ethyl)-1-metyl-1-(1-methylpiperidin-4-yl)urea 3-(1-(2,3-diklor-4-(6-cyanopyridin-3-yl)fenyl)ethyl)-1-metyl-1-(1-methylpiperidin-4-yl)urea 3-(1-(2,3-diklor-4-(6-fluoropyridin-3-yl)fenyl)ethyl)-1-metyl-1-(1-methylpiperidin-4-yl)urea 3-(1-(2,3-diklor-4-((trimethylsilyl)ethynyl)fenyl)ethyl)-1-metyl-1-(1-methylpiperidin-4-yl)urea 3-(1-(2,3-diklor-4-ethynylfenyl)ethyl)-1-metyl-1-(1-methylpiperidin-4-yl)urea 3-(1-(2,3-diklor-4-(prop-1-yn-1-yl)fenyl)ethyl)-1-metyl-1-(1-methylpiperidin-4-yl) urea 3-(1-(2,3-diklor-4-(3-metylbut-1-yn-1-yl)fenyl)ethyl)-1-metyl-1-(1-methylpiperidin-4-yl)urea

Forbindelse nr.	Kjemisk struktur	Kjemisk navn
10 H0701		3-(1-(2,3-diklor-4-(3-oksobut-1-yn-1-yl)fenyl)ethyl)-1-metyl-1-(1-metylpiriperidin-4-yl)urea
15 H0733		3-(1-(2,3-diklor-4-(3-hydroksybut-1-yn-1-yl)fenyl)ethyl)-1-metyl-1-(1-metylpiriperidin-4-yl)urea
20 H0755		3-(1-(2,3-diklor-4-(3-hydroksyprop-1-yn-1-yl)fenyl)ethyl)-1-metyl-1-(1-metylpiriperidin-4-yl)urea
25 H0757		3-(1-(2,3-diklor-4-(3,3-dietoksyprop-1-yn-1-yl)fenyl)ethyl)-1-metyl-1-(1-metylpiriperidin-4-yl)urea
30 H0734		3-(1-(2,3-diklor-4-(pyridin-2-ylethynyl)fenyl)ethyl)-1-metyl-1-(1-metylpiriperidin-4-yl)urea
35 H0737		3-(1-(2,3-diklor-4-(thiofen-2-ylethynyl)fenyl)ethyl)-1-metyl-1-(1-metylpiriperidin-4-yl)urea

Forbindelse nr.	Kjemisk struktur	Kjemisk navn
10 H0762		3-(1-(2,3-diklor-4-(furan-2-yletynyl) fenyl)ethyl)-1-metyl-1-(1-metylpiriperidin-4-yl)urea
15 H0751		3-(1-(2,3-diklor-4-(thiazol-4-yletynyl) fenyl)ethyl)-1-metyl-1-(1-metylpiriperidin-4-yl)urea
20 H0763		3-(1-(4-((1H-imidazol-4-yl)ethynyl)-2,3-diklorfenyl)ethyl)-1-metyl-1-(1-metylpiriperidin-4-yl)urea
25 H0759		3-(1-(2,3-diklor-4-(thiofen-3-yletynyl) fenyl)ethyl)-1-metyl-1-(1-metylpiriperidin-4-yl)urea
30 H0785		3-(1-(2,3-diklor-4-(3-(thiofen-2-yl)prop-1-yn-1-yl)fenyl)ethyl)-1-metyl-1-(1-metylpiriperidin-4-yl)urea
40 H0754		3-(1-(2,3-diklor-4-(thiazol-2-yletynyl) fenyl)ethyl)-1-metyl-1-(1-metylpiriperidin-4-yl)urea

Forbindelse nr.	Kjemisk struktur	Kjemisk navn
10 H0753		3-(1-(2,3-diklor-4-(pyrimidin-5-yletynyl)fenyl)ethyl)-1-metyl-1-(1-metylpiriperidin-4-yl)urea
20 H0609		3-(1-(2,3-diklor-4-(fenyletynyl)fenyl)ethyl)-1-metyl-1-(1-metylpiriperidin-4-yl)urea
30 H0764		3-(1-(2,3-diklor-4-(syklopropyletynyl)fenyl)ethyl)-1-metyl-1-(1-metylpiriperidin-4-yl)urea
35 H0818		3-(1-(2,3-diklor-4-(syklopropyletynyl)fenyl)ethyl)-1-metyl-1-(1-metylpiriperidin-4-yl)urea (enkel enantiomer)
40 H0819		3-(1-(2,3-diklor-4-(syklopropyletynyl)fenyl)ethyl)-1-metyl-1-(1-metylpiriperidin-4-yl)urea (enkel enantiomer)
50 H0855		3-(1-(3-klor-4-(syklopropyletynyl)2-fluorfenyl)ethyl)-1-metyl-1-(1-metylpiriperidin-4-yl)urea


H0811		3-(1-(2,3-diklor-4-(syklopentyletynyl)fenyl)ethyl)-1-metyl-1-(1-metylpiriperidin-4-yl)urea
-------	---	--

Forbindelse nr.	Kjemisk struktur	Kjemisk navn
H0742		3-(1-(2,3-diklor-4-ethynylfenyl)ethyl)-1-metoksy-1-(1-metylpiriperidin-4-yl)urea
H0745		3-(1-(2,3-diklor-4-ethynylfenyl)ethyl)-1-hydroksy-1-(1-metylpiriperidin-4-yl)urea
H0749		3-(1-(2,3-diklor-4-ethynylfenyl)ethyl)-1-etoksy-1-(1-metylpiriperidin-4-yl)urea

eller et farmasøytisk akseptabelt salt derav.

**15.** En forbindelse i henhold til krav 1, valgt fra gruppen bestående av:

H0816		(S)-3-(1-(2,3-diklor-4-(pyrazin-2-yl)fenyl)ethyl)-1-metyl-1-(1-metylpiriperidin-4-yl)urea
H0900		(R)-3-(1-(2,3-diklor-4-(pyrazin-2-yl)fenyl)-2,2,2-trifluoretyl)-1-metyl-1-(1-metylpiriperidin-4-yl)urea
H0847		(S)-3-(1-(2,3-diklor-4-(6-fluorpyrazin-2-yl)fenyl)ethyl)-1-metyl-1-(1-metylpiriperidin-4-yl)urea

H0860		(S)-3-(1-(2,3-diklor-4-(pyrazin-2-yl)fenyl)propyl)-1-metyl-1-(1-metylpiridin-4-yl)urea
-------	---	--

eller et farmasøytisk akseptabelt salt derav.

16. En farmasøytisk sammensetning innbefattende en terapeutisk effektiv mengde av en forbindelse i henhold til krav 1, og en eller flere farmasøytisk akseptable eksipienter.

5

17. En forbindelse i henhold til krav 1 for bruk ved en fremgangsmåte for behandling av en lidelse forbundet med ekspresjon eller aktivitet til en ghrelin reseptor i et humant subjekt, hvor nevnte lidelse er: fedme, overvekt, spiseforstyrrelse, diabetes, metabolsk syndrom, kakeksi som er et resultat av

10 kreft, hjertesvikt, emaserasjon på grunn av aldring eller AIDS, kronisk leveresykdom, kronisk obstruktiv lungesykdom, gastrointestinal lidelse, magelidelser, alkohol eller medikament misbruk,

Prader-Willi Syndrom, Binge spiselidelse, Parkinson-indusert forstoppelse og gastrisk dysostose, kjemoterapi-indusert svimmelhet og oppkast,

15 inflammasjon, smerter, eller bevegelsesssykdom.

18. Forbindelsen for bruk i henhold til krav 17, hvor nevnte metabolske syndrom er valgt fra gruppen bestående av diabetes, Type I diabetes, Type II diabetes, inadekvat glukose toleranse, insulin resistens, hyperglykemi, hyperinsulinemi, hyperlipidemi, hypertriglyseridemi, hyperkolesterolemi,

20 dyslipidema, fedme, aldring, Syndrom X, atherosklerose, hjertelidelse, slag, hypertensjon og perifer vaskulær lidelse.

19. Forbindelsen for bruk i henhold til krav 17, hvor nevnte gastriske lidelse er valgt fra gruppen bestående av post-operativ tarmslyng (POI), diabetisk gastroparese, og opioid indusert tarm dysfunksjon.

25

20. Forbindelsen for bruk i henhold til krav 17, hvor nevnte gastrointestinale lidelse er valgt fra gruppen bestående av colon irritabile syndrom, gastritt, syre refluks lidelse, gastroparese, og funksjonell dyspepsi.

21. Forbindelsen for bruk i henhold til krav 17, hvor nevnte medikament er valgt fra gruppen bestående av amfetaminer, barbiturater, benzodiazepiner, kokain, metaqualon, og opioider.